Virinchi Ltd

Virinchi Other Announcement

Virinchi Ltd has dispatched letters to shareholders with the weblink for the Annual Report for FY 2025-26, in compliance with SEBI Listing Regulations.

Virinchi Annual General Meeting

Virinchi Limited has issued a notice for its 37th Annual General Meeting, scheduled for September 30, 2026, to be conducted via video conferencing.

Virinchi Annual Report

Virinchi Ltd submitted its Annual Report and notice for the 37th AGM scheduled on September 30, 2026, to the stock exchanges.

Virinchi Board Meeting Outcome

Virinchi Ltd announced the outcome of its board meeting, including the date for its 37th Annual General Meeting and the reappointment of a director.

Virinchi Q1 FY27 Results: Net Loss of ₹2.1 Cr

Virinchi Ltd reported revenue from operations of ₹70.1 Cr (-12.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.

Key figure

Net loss ₹2.1 Cr

Virinchi Annual General Meeting

Virinchi Ltd announced voting results for a postal ballot approving the acquisition of a healthcare business division from its subsidiary, Virinchi Health Care Private Limited.

Virinchi Merger & Restructuring

Virinchi Ltd shareholders approved the slump sale acquisition of the Bristlecone Hospitals business division from its material subsidiary, Virinchi Health Care Private Limited, via postal ballot.

Virinchi Board Meeting Date

Virinchi Ltd has scheduled a board meeting for August 13, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.

Virinchi Annual General Meeting

Virinchi Limited announced the approval of postal ballot resolutions. Shareholders approved loans under Section 185 and material related party transactions with Virinchi Health Care and Vivo Bio Tech.

Virinchi Results Correction

Virinchi Limited filed revised XBRL financials for FY26 to correct EPS and PAT mismatches. The revisions follow an NSE clarification request dated June 25, 2026.

Virinchi Annual General Meeting

Virinchi Ltd seeks shareholder approval via postal ballot to acquire its healthcare division for Rs.100 Crore. Voting runs from July 12 to August 10, 2026.

Value

₹100.0 Cr

Virinchi Merger & Restructuring Worth ₹82.99 Cr

Virinchi Limited approved a slump sale acquisition of its subsidiary's healthcare division. The unit reported ₹82.99 Crore turnover, with completion expected by August 2026.

Value

₹82.99 Cr

Execution

Expected completion by August 31, 2026

Virinchi Merger & Restructuring Worth ₹100 Cr

Virinchi Limited approved the acquisition of Bristlecone Hospitals' healthcare division for Rs.100 Crore. The transaction will be executed via a slump sale from its material subsidiary.

Value

₹100.0 Cr

Execution

Transaction effective from April 1, 2026

Virinchi Annual General Meeting

Virinchi Ltd issued a postal ballot notice for shareholder approval on loans to subsidiary and material related party transactions. The outcome will be announced by July 16, 2026.

Virinchi Capital Structure Change

Virinchi Limited allotted 1,50,000 equity shares following the conversion of warrants at Rs. 25 per share. This exercise increases the company's paid-up equity capital.

Value

₹0.38 Cr

Virinchi Capital Structure Change

Virinchi Limited allotted 20,00,000 equity shares following the conversion of warrants at ₹25 per share. The ₹5 Crore transaction increases the company's total paid-up share capital.

Value

₹5.00 Cr

Virinchi Results Update

Virinchi Limited reported consolidated FY26 revenue of ₹286.13 Crore. Profitability was impacted by a one-time ₹8.43 Crore bad-debt write-off despite 20% growth in SaaS revenue.

Value

₹286.1 Cr

Virinchi Q4 FY26 Results: Net Loss of ₹15.7 Cr, Loss Widens

Virinchi Ltd reported revenue from operations of ₹66 Cr (-4.2% YoY) and a net loss of ₹15.7 Cr for Q4 FY26.

Key figure

Net loss ₹15.7 Cr

Virinchi Financial Results

Virinchi Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The board approved these results in their May 28 meeting.

Virinchi Board Meeting Date

Virinchi Limited scheduled a board meeting on May 28, 2026, to approve audited financial results. Trading window remains closed for designated persons until May 30.

Virinchi Other Announcement

Virinchi Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The auditor noted a minor one-day disclosure delay resulting in an NSE warning letter.

Virinchi Capital Structure Change

Virinchi Limited allotted 8,50,000 equity shares at Rs. 28 per share following the conversion of warrants. The total transaction value is ₹2.38 Crore. This conversion increases the company's paid-up share capital to 10,96,46,896 shares.

Value

₹2.38 Cr

Virinchi Capital Structure Change

Virinchi Limited allotted 8,50,000 equity shares to promoter group entity Vivo Bio Tech Limited following the conversion of warrants. The allotment occurred at an issue price of Rs.28 per share, with Rs.1.78 Crore received as application money. This transaction increases the company's total issued share capital to 10,96,46,896 equity shares.

Value

₹1.78 Cr

Virinchi Other Announcement

Virinchi Limited submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate from Aarthi Consultants confirms the processing of dematerialization requests and cancellation of physical share certificates within the mandated timelines. This is a routine administrative filing.

Execution

January 01, 2026 to March 31, 2026